U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Name Type Language
Renizgamglogene Autogedtemcel
INN  
Official Name English
An investigational CRISPR/Cas12a-based gene therapy that consists of autologous CD34+ hematopoietic stem cells edited at HBG1 and HG2 promoters for potential use in treating sickle cell disease and β-thalassemia
Common Name English
renizgamglogene autogedtemcel [INN]
Common Name English
autologous human CD34+ hematopoietic stem/precursor cells (HSPCs), obtained from peripheral blood by leukapheresis from plerixafor-mobilized sickle cell disease (SCD) patients or granulocyte colony stimulating factor (G-CSF) and plerixafor-mobilized tran
Common Name English
EDIT 301
Code English
EDIT-301 CD34+ hematopoietic stem cells
Common Name English
EDIT-301
Code English
Code System Code Type Description
INN
12733
Created by admin on Sat Dec 16 19:50:21 UTC 2023 , Edited by admin on Sat Dec 16 19:50:21 UTC 2023
PRIMARY
CAS
2923537-23-7
Created by admin on Sat Dec 16 19:50:21 UTC 2023 , Edited by admin on Sat Dec 16 19:50:21 UTC 2023
PRIMARY
FDA UNII
4A4FLA6DZA
Created by admin on Sat Dec 16 19:50:21 UTC 2023 , Edited by admin on Sat Dec 16 19:50:21 UTC 2023
PRIMARY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966